drugset / Trial / NCT01286675
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
NaSingle-groupOpen-labelSupportive care
Summary
Eltrombopag may improve the cell collection available for Autologous Stem Cell Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT will increase the number of blood cells collected and reduce the number of times blood needs to be collected. This study will also determine the highest dose of Eltrombopag that can be used without causing serious side effects.
Timeline
- Start
- 2011-03
- Primary completion
- 2016-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 50 mg | Oral |
| Subject | Eltrombopag | Small molecule | 100 mg | Oral |
| Subject | Eltrombopag | Small molecule | 150 mg | Oral |